ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells

ISB 2001 is a novel trispecific T cell engager (TCE) designed to combat multiple myeloma by simultaneously targeting BCMA and CD38 on tumor cells. This article details ISB 2001's superior cytotoxic potency across diverse tumor cell profiles and its ability to overcome immune escape mechanisms like antigen downregulation and soluble factor interference, outperforming existing single-target therapies like teclistamab. The article also highlights the development of an innovative quantitative systems pharmacology (QSP) model to determine an optimal, safer first-in-human dose, a methodology accepted by regulatory bodies.